[1]
|
Daly, A.F. and Beckers, A. (2020) The Epidemiology of Pituitary Adenomas. Endocrinology and Metabolism Clinics of North America, 49, 347-355. https://doi.org/10.1016/j.ecl.2020.04.002
|
[2]
|
Kontogeorgos, G. (2005) Classification and Pathology of Pituitary Tumors. Endocrine, 28, 27-35.
https://doi.org/10.1385/ENDO:28:1:027
|
[3]
|
Nishioka, H. and Inoshita, N. (2019) The 2017 WHO Classification of Pituitary Tumors. No Shinkei Geka, 47, 597-606.
|
[4]
|
燕羽佳, 刘佳雨, 阎晓玲, 等. 2017年WHO垂体肿瘤分类变化的解读与分析[J]. 中国微侵袭神经外科杂志, 2020, 25(11): 525-528.
|
[5]
|
刘涵. 垂体瘤患者临床特征、诊治及术后综合管理的探究[D]: [硕士学位论文]. 济南: 山东大学, 2021.
|
[6]
|
Cohn, A., Li, C.Y.L., Hoffman, S.E., et al. (2021) Characterization of Gonadotroph Pituitary Adenomas Based on the Recent 2017 WHO Pituitary Tumor Classi-fication. Journal of the Endocrine Society, 5, A640-A641.
https://doi.org/10.1210/jendso/bvab048.1305
|
[7]
|
Asa, S.L., Mete, O., Perry, A., et al. (2022) Overview of the 2022 WHO Classification of Pituitary Tumors. Endocrine Pathology, 33, 6-26. https://doi.org/10.1007/s12022-022-09703-7
|
[8]
|
Pérezlópez, C., Zamarrón, Á., Isla, A., et al. (2021) Is the Cur-rent WHO Classification of Pituitary Adenomas Practical? Endocrinologia, Diabetes y Nutricion, 69, 234-235.
|
[9]
|
Asa, S.L., Mete, O., Cusimano, M.D., et al. (2021) Pituitary Neuroendocrine Tumors: A Model for Neuroendocrine Tumor Classification. Modern Pathology, 34, 1634-1650. https://doi.org/10.1038/s41379-021-00820-y
|
[10]
|
Asa, S.L., Asioli, S., Bozkurt, S., et al. (2020) Pituitary Neuroendocrine Tumors (PitNETs): Nomenclature Evolution, Not Clinical Revolution. Pituitary, 23, 322-325. https://doi.org/10.1007/s11102-019-01015-0
|
[11]
|
Rindi, G., Klimstra, D.S., Abedi-Ardekani, B., et al. (2018) A Common Classification Framework for Neuroendocrine Neoplasms: An Internation-al Agency for Research on Cancer (IARC) and World Health Organization (WHO) Expert Consensus Proposal. Modern Pathology, 31, 1770-1786. https://doi.org/10.1038/s41379-018-0110-y
|
[12]
|
Williams, M.D., Harris, R., Dayan, C.M., et al. (2009) Thyroid Function and the Natural History of Depression: Findings from the Caerphilly Prospective Study (CaPS) and a Meta-Analysis. Clinical Endocrinology, 70, 484-492.
https://doi.org/10.1111/j.1365-2265.2008.03352.x
|
[13]
|
Nasr, C., Mason, A., Mayberg, M., et al. (2006) Acromeg-aly and Somatotroph Hyperplasia with Adenomatous Transformation Due to Pituitary Metastasis of a Growth Hor-mone-Releasing Hormone-Secreting Pulmonary Endocrine Carcinoma. The Journal of Clinical Endocrinology and Me-tabolism, 91, 4776-4780. https://doi.org/10.1210/jc.2006-0610
|
[14]
|
Feola, T., Carbonara, F., Verrico, M., et al. (2022) Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art. Cancers, 14, Article No. 4093. https://doi.org/10.3390/cancers14174093
|
[15]
|
Nie, D., Zhao, P., Li, C.Z., et al. (2022) Application of “Mosiac Sign” on T2-WI in Predicting the Consistency of Pituitary Neuroendocrine Tumors. Frontiers in Surgery, 9, Article ID: 922626.
https://doi.org/10.3389/fsurg.2022.922626
|
[16]
|
唐晓爽, 张晓青, 尹华春, 等. 无功能垂体腺瘤的垂体相关转录因子表达与临床特征分析[J]. 中国临床神经外科杂志, 2021, 26(12): 907-911.
|
[17]
|
Manojlovic-Gacic, E., Eng-ström, B.E. and Casar-Borota, O. (2018) Histopathological Classification of Non-Func- tioning Pituitary Neuroendocrine Tumors. Pituitary, 21, 119-129. https://doi.org/10.1007/s11102-017-0855-1
|
[18]
|
Mete, O., Kefeli, M., Çalışkan, S. and Asa, S.L. (2019) GATA3 Immunoreactivity Expands the Transcription Factor Profile of Pituitary Neuroendocrine Tumors. Modern Pathology, 32, 484-489.
https://doi.org/10.1038/s41379-018-0167-7
|
[19]
|
Ben-Shlomo, A., Deng, N., Ding, E., et al. (2020) DNA Damage and Growth Hormone Hypersecretion in Pituitary Somatotroph Adenomas. The Journal of Clinical Investigation, 130, 5738-5755. https://doi.org/10.1172/JCI138540
|
[20]
|
Wolfgang, S. (2021) WHO-Klassifikation der Hypophysen-tumoren des Jahres 2017. Der Pathologe, 42, 333-351.
https://doi.org/10.1007/s00292-021-00932-x
|
[21]
|
Ho, K.K.Y., Gadelha, M., Kaiser, U.B., et al. (2022) The NET-ting of Pituitary Adenoma: A Gland Illusion. Pituitary, 25, 349-351. https://doi.org/10.1007/s11102-022-01235-x
|
[22]
|
Asa, S.L., et al. (2017) From Pituitary Adenoma to Pituitary Neuroendocrine Tumor (PitNET): An International Pituitary Pathology Club Proposal. Endocrine-Related Cancer, 24, C5-C8. https://doi.org/10.1530/ERC-17-0004
|
[23]
|
Serioli, S., Doglietto, F., Fiorindi, A., et al. (2019) Pituitary Adenomas and Invasiveness from Anatomo-Surgical, Radiological, and Histological Perspectives: A Systematic Litera-ture Review. Cancers, 11, Article No. 1936.
https://doi.org/10.3390/cancers11121936
|
[24]
|
Jiang, S.Z., Zhu, J.Y., Feng, M., et al. (2021) Clinical Profiles of Silent Corticotroph Adenomas Compared with Silent Gonadotroph Adenomas after Adopting the 2017 WHO Pituitary Classification System. Pituitary, 24, 564-573.
|
[25]
|
Connor, S.E., Wilson, F. and Hogarth, K. (2014) Magnetic Reso-nance Imaging Criteria to Predict Complete Excision of Parasellar Pituitary Macroadenoma on Postoperative Imaging. Journal of Neurological Surgery. Part B, Skull Base, 75, 41-46. https://doi.org/10.1055/s-0033-1353362
|
[26]
|
Ilie, M.D., Vasiljevic, A., Bertolino, P., et al. (2022) Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary Adenomas. Endocrine Reviews, 44, 297-311. https://doi.org/10.1210/endrev/bnac024
|
[27]
|
Stefanidis, P., Kyriakopoulos, G., Seretis, A.M., et al. (2022) Prognostic Factors for Invasiveness and Recurrence of Pituitary Adeno-mas: A Series of 94 Patients. Diagnostics (Basel, Switzerland), 12, Article No. 2413.
https://doi.org/10.3390/diagnostics12102413
|
[28]
|
Rosinha, P., Fonseca, L., Amaral, C., et al. (2022) Pituitary Ad-enomas in the Elderly: Retrospective Comparative Analysis of Clinical/Tumor Features and Surgical Data by Age Group. Medicine, 101, e30825.
https://doi.org/10.1097/MD.0000000000030825
|
[29]
|
Zhang, F., Zhang, Q., Zhu, J., et al. (2022) Integrated Prote-ogenomic Characterization across Major Histological Types of Pituitary Neuroendocrine Tumors. Cell Research, 32, 1047-1067. https://doi.org/10.1038/s41422-022-00736-5
|
[30]
|
Guaraldi, F., Morandi, L., Zoli, M., et al. (2022) Epigenomic and Somatic Mutations of Pituitary Tumors with Clinical and Pathological Correlations in 111 Patients. Clin-ical Endocrinology, 97, 763-772. https://doi.org/10.1111/cen.14827
|
[31]
|
Hickman, R.A., Bruce, J.N., Otten, M., et al. (2021) Gonadotroph Tumours with a Low SF-1 Labelling Index Are More Likely to Recur and Are Associated with Enrichment of the PI3K-AKT Pathway. Neuropathology and Applied Neurobiology, 47, 415-427. https://doi.org/10.1111/nan.12675
|
[32]
|
Mcdonald, W.C., Banerji, N., Mcdonald, K.N., et al. (2017) Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A Rational Starting Place for the Immunohistochemical Characteriza-tion of Pituitary Adenoma. Archives of Pathology & Laboratory Medicine, 141, 104-112. https://doi.org/10.5858/arpa.2016-0082-OA
|
[33]
|
Sjöstedt, E., Bollerslev, J., Mulder, J., et al. (2017) A Specific Antibody to Detect Transcription Factor T-Pit: A Reliable Marker of Corticotroph Cell Differentiation and a Tool to Im-prove the Classification of Pituitary Neuroendocrine Tumours. Acta Neuropathologica, 134, 675-677. https://doi.org/10.1007/s00401-017-1768-9
|
[34]
|
Burcea, I.F., Năstase, V.N. and Poiană, C. (2021) Pituitary Tran-scription Factors in the Immunohistochemical and Molecular Diagnosis of Pituitary Tumours—A Systematic Review. Endokrynologia Polska, 72, 53-63.
https://doi.org/10.5603/EP.a2020.0090
|
[35]
|
Trouillas, J., Jaffrain-Rea, M.L., Vasiljevic, A., et al. (2020) Are Ag-gressive Pituitary Tumors and Carcinomas Two Sides of the Same Coin? Pathologists Reply to Clinician’s Questions. Reviews in Endocrine & Metabolic Disorders, 21, 243-251. https://doi.org/10.1007/s11154-020-09562-9
|
[36]
|
Trouillas, J., Jaffrain-Rea, M.L., Vasiljevic, A., et al. (2020) How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020. Cancers, 12, Article No. 514. https://doi.org/10.3390/cancers12020514
|